Economy

Drugmakers Outline Obesity Treatment Strategies and Pricing Deals at Industry Conference

Illustration for: Drugmakers Outline Obesity Treatment Strategies and Pricing Deals at Industry Conference
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Jan 14, 2026

THE BARE STORY

Major pharmaceutical companies have released updates regarding their drug pipelines and business strategies, with a strong emphasis on weight loss treatments and navigating new pricing dynamics. During presentations at the JPMorgan Healthcare Conference, executives detailed plans to address obesity management and respond to shifting regulatory environments.

Amgen CEO Bob Bradway presented trial results for the company's experimental drug, MariTide, stating that patients maintained weight loss over a two-year period. Bradway noted the treatment is being tested for monthly or potentially quarterly administration, aiming to solve what he termed a "patient persistence issue." Similarly, Pfizer CEO Albert Bourla declared his company is "all in on obesity" following its approximately $10 billion acquisition of Metsera, while Novo Nordisk CEO Mike Doustdar stated that new oral and injectable drugs are expected to further expand the market.

Executives also addressed the economic landscape. Doustdar predicted 2026 would be a year of price pressure following a pricing agreement with President Donald Trump. Separately, AbbVie reached a deal with the Trump administration to lower certain drug prices and invest $100 billion domestically over the next decade. In exchange, the company secured exemptions from tariffs and future pricing mandates, a move consistent with agreements made by other large drugmakers.

In other industry developments, Eli Lilly and Nvidia announced a joint investment of up to $1 billion to create a laboratory utilizing artificial intelligence for drug discovery. Bristol Myers Squibb CEO Chris Boerner outlined plans to introduce up to 10 new products by the end of the decade to offset patent expirations. Additionally, Amgen reported positive progress in integrating its acquisition of Horizon Therapeutics, which focuses on biologics for autoimmune conditions.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Perspective by Claude

• Major investment in obesity treatments Executives from multiple companies highlighted significant commitments to the weight loss market, with Pfizer’s CEO declaring the company is "all in on obesity" following a roughly $10 billion acquisition. Similarly, Novo Nordisk plans to expand the market through new oral and injectable options, while Amgen presented trial results for its experimental drug, MariTide.

• Integration of technology and pipeline growth Beyond weight loss, companies are leveraging advanced technology to drive discovery, exemplified by Eli Lilly and Nvidia’s joint investment of up to $1 billion to build an AI-powered laboratory. Meanwhile, Bristol Myers Squibb aims to launch up to 10 new products this decade to counter the impact of patent expirations.

• Improvements in patient administration Companies are specifically targeting the "patient persistence issue" by developing treatments with less frequent dosing schedules. Amgen noted that its new therapy is being tested for monthly or potentially quarterly administration to help patients maintain weight loss over a two-year period.

How it may affect me

As a U.S. reader: Patients seeking weight loss management may soon have access to new oral and injectable options, including treatments requiring only monthly or quarterly administration to improve long-term adherence.

You could experience lower costs for certain drugs following agreements between manufacturers and the government, though executives warn of potential price pressures returning by 2026.

Domestic investment may increase as companies like AbbVie pledge $100 billion to U.S. operations over the next decade in exchange for exemptions from tariffs and future pricing mandates.

Future therapies could reach the market faster as Eli Lilly and Nvidia invest up to $1 billion into artificial intelligence laboratories dedicated to accelerating drug discovery.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.